CCA to Issue 13.88 Million Shares in Connection With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CCA to Issue 13.88 Million Shares in Connection With Special Dividend

NASHVILLE, TN--(Marketwired - May 16, 2013) - CCA (NYSE: CXW) (the "Company" or "Corrections Corporation of America"), today announced that it will issue approximately 13.88 million new shares of its common stock in connection with the payment of the Company's previously announced special dividend. The shares to be issued represent 80% of the total value of the $675 million special dividend. The number of shares to be issued was determined based upon the average closing price on the three trading days following May 9, 2013, or $38.90 per share. The remaining 20%, or $135 million of the special dividend, will be paid in cash. As the aggregate amount of cash elected by stockholders exceeded the 20% maximum established, the available cash will be prorated among those stockholders based on their elections. All stockholders will also receive cash in lieu of fractional shares, if any. The special dividend is payable on May 20, 2013 to stockholders of record as of the close of business on April 19, 2013. Following payment of the special dividend, the Company will have approximately 115.2 million shares of its common stock outstanding. The special dividend is the final step necessary to complete the Company's conversion to a real estate investment trust (REIT) effective as of January 1, 2013. 

Updated Guidance

On May 8, 2013, CCA issued guidance, which was calculated without including any adjustment for the additional shares that would be issued in connection with the special dividend. Therefore, the Company is providing the following updated guidance incorporating the impact of the additional shares to be issued:

Second Quarter 2013

  • Adjusted Diluted EPS of $0.49 to $0.50
  • Normalized Funds From Operations per diluted share of $0.66 to $0.68
  • Adjusted Funds From Operations per diluted share of $0.65 to $0.66
  • Assumes 109.1 million weighted average shares outstanding for the second quarter of 2013

Full Year 2013

  • Adjusted Diluted EPS of $1.91 to $1.98
  • Normalized Funds From Operations per diluted share of $2.60 to $2.67
  • Adjusted Funds From Operations per diluted share of $2.53 to $2.65
  • Assumes 111.5 million weighted average shares outstanding for the full-year of 2013

No other adjustments have been made to guidance. The guidance excludes REIT conversion costs, debt refinancing costs, and the reversal of certain net deferred tax liabilities associated with the REIT conversion. 

 
 
Calculation of FFO and AFFO Per Share Guidance
 
    For the Quarter Ending June 30, 2013     For the Year Ending December 31, 2013  
    Low End of Guidance     High End of Guidance     Low End of Guidance     High End of Guidance  
Adjusted net income   $ 53,000     $ 54,000     $ 213,000     $ 221,000  
Depreciation on real estate assets     19,000       20,000       77,000       77,000  
Funds From Operations   $ 72,000     $ 74,000     $ 290,000     $ 298,000  
                                 
Other non-cash expenses     4,300       4,400       17,000       17,000  
Maintenance capital expenditures on real estate assets     (5,250 )     (6,250 )     (25,000 )     (20,000 )
Adjusted Funds From Operations   $ 71,050     $ 72,150     $ 282,000     $ 295,000  
                                 
Funds From Operations Per Diluted Share   $ 0.66     $ 0.68     $ 2.60     $ 2.67  
Adjusted Funds From Operations Per Diluted Share   $ 0.65     $ 0.66     $ 2.53     $ 2.65  
                                 
                                 

FFO and AFFO are widely accepted non-GAAP supplemental measures of REIT performance following the standards established by the National Association of Real Estate Investment Trusts (NAREIT). CCA believes that FFO and AFFO are important operating measures that supplement discussion and analysis of the Company's results of operations and are used to review and assess operating performance of the Company and its correctional facilities and their management teams. NAREIT defines FFO as net income computed in accordance with generally accepted accounting principles, excluding gains (or losses) from sales of property and extraordinary items, plus depreciation and amortization of real estate and impairment of depreciable real estate. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), this accounting presentation assumes that the value of real estate assets diminishes at a level rate over time. Because of the unique structure, design and use of the Company's correctional facilities, management believes that assessing performance of the Company's correctional facilities without the impact of depreciation or amortization is useful. CCA may make adjustments to FFO from time to time for certain other income and expenses that it considers non-recurring, infrequent or unusual, even though such items may require cash settlement, because such items do not reflect a necessary component of the ongoing operations of the Company. Normalized FFO excludes the effects of such items. CCA calculates AFFO by adding to Normalized FFO non-cash expenses such as the amortization of deferred financing costs and stock-based compensation, and by subtracting from Normalized FFO normalized recurring real estate expenditures that are capitalized and then amortized, but which are necessary to maintain a REIT's properties and its revenue stream. Some of these capital expenditures contain a discretionary element with respect to when they are incurred, while others may be more urgent. Therefore, these capital expenditures may fluctuate from quarter to quarter, depending on the nature of the expenditures required, seasonal factors such as weather, and budgetary conditions. Other companies may calculate FFO, Normalized FFO, and AFFO differently than the Company does, or adjust for other items, and therefore comparability may be limited. FFO, Normalized FFO, and AFFO and their corresponding per share measures are not measures of performance under GAAP, and should not be considered as an alternative to cash flows from operating activities, a measure of liquidity or an alternative to net income as indicators of the Company's operating performance or any other measure of performance derived in accordance with GAAP. This data should be read in conjunction with the Company's consolidated financial statements and related notes included in its filings with the Securities and Exchange Commission.

About CCA

CCA is the nation's largest owner of partnership correction and detention facilities and one of the largest prison operators in the United States, behind only the federal government and three states. We operate 67 facilities, including 51 facilities that we own or control, with a total design capacity of approximately 92,500 beds in 20 states and the District of Columbia. CCA specializes in owning, operating and managing prisons and other correctional facilities and providing inmate residential services for governmental agencies. In addition to providing the fundamental residential services relating to inmates, our facilities offer a variety of rehabilitation and educational programs, including basic education, religious services, life skills and employment training and substance abuse treatment. 

Forward-Looking Statements

This press release contains statements as to the Company's beliefs and expectations of the outcome of future events that are forward-looking statements as defined within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These include, but are not limited to, the risks and uncertainties associated with: (i) our ability to meet and maintain REIT qualification tests; (ii) general economic and market conditions, including the impact governmental budgets can have on our per diem rates, occupancy and overall utilization; (iii) the availability of debt and equity financing on terms that are favorable to us; (iv) fluctuations in our operating results because of, among other things, changes in occupancy levels, competition, increases in cost of operations, fluctuations in interest rates and risks of operations; (v) our ability to obtain and maintain correctional facility management contracts, including as a result of sufficient governmental appropriations and as a result of inmate disturbances; (vi) changes in the privatization of the corrections and detention industry, the public acceptance of our services, the timing of the opening of and demand for new prison facilities and the commencement of new management contracts; (vii) changes in government policy and in legislation and regulation of the corrections and detention industry, which may adversely affect our business, including the impact of the Budget Control Act of 2011 on federal corrections budgets, California's utilization of out of state private correctional capacity, and the impact of any changes to immigration reform laws; and (viii) increases in costs to construct or expand correctional facilities that exceed original estimates, or the inability to complete such projects on schedule as a result of various factors, many of which are beyond our control, such as weather, labor conditions and material shortages, resulting in increased construction costs.

Contact: Investors and Analysts: Karin Demler CCA (615) 263-3005 Financial Media: David Gutierrez Dresner Corporate Services (312) 780-7204

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Savvas Launches Miller & Levine Biology Program Revamp

Updated Category News Views 35

Education Meets Innovation: Savvas Takes a Bold Step Who would have thought biology education could get a makeover that might actually stick? Savvas Learning Company thinks it's onto something with the launch of the all-new Miller & Levine Experience Biology Program. The spotlight's on innovation—it's about time someone shook up the way high schoolers learn biology. A...

Continue Reading
Factory-Built Homes Take Center Stage in New Doc Short

Updated Category News Views 88

Housing is one of those things we all think we understand until we start peeling back the layers of its history, especially when factory-built homes are involved. Here's a new angle: Clayton has just released the teaser for their documentary short, "Built: A Story of Factory-Built Housing in America," and it's turning the lights on a sector that's often left in the...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Unicycive Faces Legal Heat: Shareholder Lawsuit Looms

Updated Category News Views 104

The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...

Continue Reading
SoftwareOne Triumphs in 2026 GitHub Partner Awards

Updated Category News Views 43

SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...

Continue Reading
Data Centers Drive Surge in Power and Cooling Demand

Updated Category News Views 23

Data Centers: The Unseen Powerhouses Don't let the tech jargon fool you—data centers are more than just server rooms. They're beastly energy guzzlers, and their demand is rippling through the supply chain in a big way. You've got companies like Vertiv, American Tower, Johnson Controls, and Generac riding high on this trend, making some serious waves in their quarterly...

Continue Reading
Data Breach at Lumara Bio: Privacy Lawsuits Loom

Updated Category News Views 28

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Continue Reading
Jacobi's Harness Brings AI from Concept to Reality

Updated Category News Views 160

The Challenge of Moving AI to Production Diving headfirst into AI in finance? Well, Jacobi's bold move with their new toy, the Investment Management Harness, spotlights a filthy secret: the hurdles between a big idea and execution are seldom technological. We got AI shaving prototyping time down to just days, yet pushing to production? That's a marathon in itself. Boards...

Continue Reading
Air Canada-CAE Scholarship Drives Women in Aviation

Updated Category News Views 88

A New Chapter for Women in Aviation Call it paving the skies or busting the glass cockpit ceiling, but Air Canada and CAE are really doubling down on getting more women into aviation. They're rolling out the eighth annual Captain Judy Cameron Scholarship, set to open applications on November 1, 2026. With up to eight scholarships on the table for Canadian women eyeing...

Continue Reading
H.R. 10549: Hope Charities Pushes for Pharmacy Freedom

Updated Category News Views 63

Hope Charities Takes a Stand for Patients In Prairieville, Hope Charities is throwing its weight behind a bill they believe is brewing up a patient revolution. The Patients Choice in Specialty Pharmacy Act, otherwise known as H.R. 10549, sparked by Representatives Neal Dunn and Joe Wilson, tackles the comfortable partnerships some insurers have been enjoying with their...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading